Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier

International Journal of Cancer

Volumn 126, Issue 2, 2010, Pages 533-544

  Massodi, Iqbal ^a   Moktan, Shama ^a   Rawat, Aruna ^a   Bidwell III, Gene L ^a   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Drug delivery; Elastin like polypeptide; Hyperthermia; p21; Thermal targeting

Indexed keywords

BAC ELP1 P21 FUSION PROTEIN; BETA TUBULIN; CASPASE; CELL PENETRATING PEPTIDE; ELASTIN LIKE POLYPEPTIDE; HYBRID PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYPEPTIDE; PROTEIN BAC 7; PROTEIN P21; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIA; MACROMOLECULE; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SOLID TUMOR; WESTERN BLOTTING;

AMINO ACID SEQUENCE; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ELASTIN; FEMALE; HOT TEMPERATURE; HUMANS; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PEPTIDES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINANT FUSION PROTEINS; RETINOBLASTOMA PROTEIN; TRANSITION TEMPERATURE;

EID: 73549108720     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24725     Document Type: Article

References (49)

1. Allen TM. Liposomal drug formulation: rationale for development and what we can expect in the future. Drugs 1998;56:747-56.
2. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004;94:1-14.
3. Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 1998;15:1-19.
4. Langer R. Drug delivery and targeting. Nature (Lond.) 1998;392 (Suppl.):5-10.
5. Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer 2005;12 (Suppl 1): S189-99.
6. Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000;50:61-81.
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60.
8. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701.
9. Takakura Y, Fujita T, Hashida M, Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res 1990;7: 339-46.
10. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992;3:351-62.
11. Cassidy J, Duncan R, Morrison GJ, Strohalm J, Plocova D, Kopecek J, Kaye SB. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol 1989;38:875-9.
12. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83:601-6.
13. Gius DR, Ezhevsky SA, Becker-Hapak M, Nagahara H, Wei MC, Dowdy SF. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res 1999;59: 2577-80.
14. Hosotani R, Miyamoto Y, Fujimoto K, Doi R, Otaka A, Fujii N, Imamura M. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res 2002;8:1271-6.
15. Ball KL, Lain S, Fahraeus R, Smythe C, Lane DP. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 1997;7:71-80.
16. Bonfanti M, Taverna S, Salmona M, D'Incalci M, Broggini M. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 1997;57:1442-6.
17. Urry DW, Luan C-H, Parker TM, Gowda DC, Prasad KU, Reid MC, Safavy A. Temperature of Polypeptide Inverse Temperature Transition Depends on Mean Residue Hydrophobicity. J Am Chem Soc. 1991;113:4346-8.
18. Tatham AS, Shewry PR. Elastomeric proteins: biological roles, structures and mechanisms. Trends Biochem Sci 2000;25:567-71.
19. Meyer DE, Kong GA, Dewhirst MW, Zalutsky MR, Chilkoti A. Targeting a Genetically Engineered Elastin-like Polypeptide to Solid Tumors by Local Hyperthermia. Cancer Res 2001;61:1548-54.
20. Liu W, Dreher MR, Furgeson DY, Peixoto KV, Yuan H, Zalutsky MR, Chilkoti A. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release 2006;116:170-8.
21. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Chilkoti A. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res 2007;67:4418-24.
22. Fujiwara K, Watanabe T. Effects of hyperthermia, radiotherapy and thermoradiotherapy on tumor microvascular permeability. Acta Pathol Jpn 1990;40:79-84.
23. Gerlowski LE, Jain RK. Effect of hyperthermia on microvascular permeability to macromolecules in normal and tumor tissues. Int J Microcirc Clin Exp 1985;4:363-72.
24. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559-93.
25. Temsamani J, Guinot P. Antisense oligonucleotides: a new therapeutic approach. Biotechnology & Applied Biochemistry 1997;26: 65-71.
26. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004;2:E36.
27. Nori A, Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005;57:609-36.
28. Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 2004;9:1012-19.
29. Massodi I, Bidwell GL, 3rd, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 2005;108:396-408.
30. Massodi I, Raucher D. A thermally responsive Tat-elastin-like polypeptide fusion protein induces membrane leakage, apoptosis, and cell death in human breast cancer cells. J Drug Target 2007; 15:611-22.
31. Bidwell GL, 3rd, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 2007;73:620-31.
32. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 2002;41:14150-7.
33. Bidwell GL, 3rd, Davis AN, Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release 2009;135:2-10.
34. Mutoh M, Lung FD, Long YQ, Roller PP, Sikorski RS, O'Connor PM. A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res 1999;59:3480-8.
35. Warbrick E, Lane DP, Glover DM, Cox LS. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol 1995;5:275-82.
36. Chilkoti A, Dreher MR, Meyer DE. Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery. Adv Drug Deliv Rev 2002;54:1093-111.
37. Bidwell GL, 3rd, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005;4:1076-85.
38. Meyer DE, Chilkoti A. Purification of Recombinant Proteins by Fusion with Thermally Responsive Polypeptides. Nat Biotechnol 1999;17:1112-15.
39. Tomasinsig L, Skerlavaj B, Papo N, Giabbai B, Shai Y, Zanetti M. Mechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cells. J Biol Chem 2006; 281:383-91.
40. Mattock H, Lane DP, Warbrick E. Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Exp Cell Res 2001;265:234-41.
41. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA 1999;96:1002-7.
42. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25:5220-7.
43. Huo JX, Metz SA, Li GD. p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ 2004; 11:99-109.
44. Bidwell GL, 3rd, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006;71:248-56.
45. Bidwell GL, 3rd, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 2007;25:313-26.
46. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. Faseb J 2006; 20: 1775-84.
47. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995;375:159-61.
48. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
49. Baker RD, Howl J, Nicholl ID. A sychnological cell penetrating peptide mimic of p21(WAF1/CIP1) is proapoptogenic. Peptides 2007; 28:731-40.